Vanguard Group Inc Biocryst Pharmaceuticals Inc Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Vanguard Group Inc holds 20,306,596 shares of BCRX stock, worth $143 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,306,596
Previous 18,769,493
8.19%
Holding current value
$143 Million
Previous $116 Million
33.05%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding BCRX
# of Institutions
279Shares Held
172MCall Options Held
625KPut Options Held
739K-
Black Rock Inc. New York, NY20MShares$140 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$83.4 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$63.9 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$62.2 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$57.2 Million1.15% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.31B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...